The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the design and updated findings of the Phase II ZUMA-5 study evaluating axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (NHL) (NCT03105336). This study included patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL) who had received at least two lines of prior therapy. The study reported overall response rates (ORR) of 94% and 83% and complete response (CR) rates of 79% and 63% in patients with FL and MZL respectively. In addition, 57% and 50% of patients with FL and MZL respectively were still in remission at data cutoff. Axi-cel demonstrated a manageable safety profile, with mostly grade 1 or 2 cytokine release syndrome (CRS) and neurological events. In addition, patients with follicular lymphoma experienced less grade 3 or higher neurological adverse events than patients with MZL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
